Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05765734




Registration number
NCT05765734
Ethics application status
Date submitted
8/02/2023
Date registered
13/03/2023

Titles & IDs
Public title
A Study of TAS3351 in NSCLC Patients With EGFRmt
Scientific title
A Phase 1/2 Study of TAS3351 in Patients With Advanced Non-Small Cell Lung Cancer and EGFR Mutations
Secondary ID [1] 0 0
2022-502595-23
Secondary ID [2] 0 0
10073010
Universal Trial Number (UTN)
Trial acronym
TAS3351
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - TAS3351 oral administration

Experimental: TAS3351 Part A (Dose Escalation) - Dose escalation will assess the safety and determine the recommended phase 2 dose and regimen of TAS3351 administered orally.

Experimental: TAS3351 Part B (Dose Expansion) - TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose determined in Part A.

Experimental: TAS3351 Part C (Phase 2) - To assess efficacy of TAS3351 in NSCLC patients with C797S EGFRmt. TAS3351 will be administered at the recommended phase 2 dose.


Treatment: Drugs: TAS3351 oral administration
TAS3351 will be administered orally
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Dose Escalation: To investigate the safety and determine the recommended Phase 2 dose and dosing schedule of TAS3351
Timepoint [1] 0 0
baseline through cycle 1(each cycle is 21 days)
Primary outcome [2] 0 0
Dose Escalation: To investigate the safety and determine the recommended Phase 2 dose and dosing schedule of TAS3351
Timepoint [2] 0 0
baseline through cycle 1(each cycle is 21 days)
Primary outcome [3] 0 0
Dose Expansion: To explore the efficacy of TAS3351
Timepoint [3] 0 0
estimated 9 months
Primary outcome [4] 0 0
Phase 2: To assess the efficacy of TAS3351
Timepoint [4] 0 0
estimated 3 years
Secondary outcome [1] 0 0
Dose Escalation:To evaluate the antitumor activity of TAS3351
Timepoint [1] 0 0
estimated 20 months
Secondary outcome [2] 0 0
Dose Escalation:To evaluate the antitumor activity of TAS3351
Timepoint [2] 0 0
estimated 20 months
Secondary outcome [3] 0 0
Dose Escalation:To evaluate the antitumor activity of TAS3351
Timepoint [3] 0 0
estimated 20 months
Secondary outcome [4] 0 0
Dose Escalation: To evaluate the antitumor activity of TAS3351
Timepoint [4] 0 0
estimated 20 months
Secondary outcome [5] 0 0
Dose Escalation: To evaluate the antitumor activity of TAS3351
Timepoint [5] 0 0
estimated 20 months
Secondary outcome [6] 0 0
Dose Escalation: To characterize the pharmacokinetics (PK) of TAS3351
Timepoint [6] 0 0
Cycle 1 Day 1 through cycle 1 Day 15 (21-Day cycle)
Secondary outcome [7] 0 0
Dose Escalation: To characterize the pharmacokinetics (PK) of TAS3351
Timepoint [7] 0 0
ECycle 1 Day 1 through cycle 1 Day 15 (21-Day cycle)
Secondary outcome [8] 0 0
Dose Expansion: To confirm the safety and tolerability of TAS3351 at the recommended phase 2 dose and dosing schedule
Timepoint [8] 0 0
estimated 9 months
Secondary outcome [9] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [9] 0 0
estimated 9 months
Secondary outcome [10] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [10] 0 0
estimated 9 months
Secondary outcome [11] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [11] 0 0
estimated 9 months
Secondary outcome [12] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [12] 0 0
estimated 9 months
Secondary outcome [13] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [13] 0 0
estimated 9 months
Secondary outcome [14] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [14] 0 0
estimated 9 months
Secondary outcome [15] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [15] 0 0
estimated 9 months
Secondary outcome [16] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [16] 0 0
estimated 9 months
Secondary outcome [17] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [17] 0 0
estimated 9 months
Secondary outcome [18] 0 0
Dose Expansion: To further explore the anti-tumor efficacy of TAS3351
Timepoint [18] 0 0
estimated 9 months
Secondary outcome [19] 0 0
Phase 2: To evaluate the safety and tolerability of TAS3351
Timepoint [19] 0 0
estimated 3 years
Secondary outcome [20] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [20] 0 0
estimated 3 years
Secondary outcome [21] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [21] 0 0
estimated 3 years
Secondary outcome [22] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [22] 0 0
estimated 3 years
Secondary outcome [23] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [23] 0 0
estimated 3 years
Secondary outcome [24] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [24] 0 0
estimated 3 years
Secondary outcome [25] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [25] 0 0
estimated 3 years
Secondary outcome [26] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [26] 0 0
estimated 3 years
Secondary outcome [27] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [27] 0 0
estimated 3 years
Secondary outcome [28] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [28] 0 0
estimated 3 years
Secondary outcome [29] 0 0
Phase 2: To further assess the efficacy of TAS3351
Timepoint [29] 0 0
estimated 3 years
Secondary outcome [30] 0 0
Phase 2:To evaluate patient reported outcomes (PROs)
Timepoint [30] 0 0
estimated 3 years

Eligibility
Key inclusion criteria
* Locally advanced, non-resectable or metastatic NSCLC
* Have adequate organ function
* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
* Has tumor tissue available to allow for analysis of EGFRmt status

Dose Escalation:

• Has any EGFRmt status

Dose Escalation back-fill part, Dose Expansion and Phase II:

* Has any sensitizing EGFRmt and a confirmed C797S EGFRmt
* Has measurable disease per RECIST v1.1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participating in medical research not compatible with this study
* Symptomatic and unstable CNS metastases
* Have not recovered from prior cancer treatment
* Have a significant cardiac condition
* Are a pregnant or breastfeeding female
* A serious illness or medical condition
* Unable to swallow or digest pills

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/05/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2027
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
District of Columbia
Country [2] 0 0
United States of America
State/province [2] 0 0
Tennessee
Country [3] 0 0
United States of America
State/province [3] 0 0
Texas
Country [4] 0 0
United States of America
State/province [4] 0 0
Virginia
Country [5] 0 0
France
State/province [5] 0 0
Val De Marne
Country [6] 0 0
Germany
State/province [6] 0 0
Nordrhein Westfalen
Country [7] 0 0
Italy
State/province [7] 0 0
Milano
Country [8] 0 0
Japan
State/province [8] 0 0
Chiba-Ken
Country [9] 0 0
Japan
State/province [9] 0 0
Shizuoka-Ken
Country [10] 0 0
Japan
State/province [10] 0 0
Koto-Ku
Country [11] 0 0
Korea, Republic of
State/province [11] 0 0
Seoul
Country [12] 0 0
Korea, Republic of
State/province [12] 0 0
Seul
Country [13] 0 0
Netherlands
State/province [13] 0 0
Amsterdam
Country [14] 0 0
Netherlands
State/province [14] 0 0
Leiden
Country [15] 0 0
Spain
State/province [15] 0 0
Barcelona
Country [16] 0 0
Spain
State/province [16] 0 0
Madrid
Country [17] 0 0
United Kingdom
State/province [17] 0 0
Greater Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Taiho Oncology, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Taiho Oncology, Inc
Address 0 0
Country 0 0
Phone 0 0
+1 844-878-2446
Fax 0 0
Email 0 0
medicalinformation@taihooncology.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05765734